Medapine is a retinoid-like compound. Biochemical and pharmacological profile studies have demonstrated that adapalene is a potent modulator of cellular differentiation, keratinisation and inflammatory processes all of which represent important features in the pathology of acne vulgaris. Medapine binds to specific retinoic acid nuclear receptors that normalises the differentiation of follicular epithelial cells resulting in decreased microcomedone formation.
Medapine cream is used for the topical treatment of acne vulgaris of the face, chest or back.
Medapine is also used to associated treatment for these conditions: Acne Vulgaris
|Adapalene Other Names||Adapalene, Adapalène, Adapaleno, Adapalenum|
|Therapeutic Class||Topical retinoid and related preparations|
|Manufacturer||Ranbaxy Laboratories (sun Pharma)|
|Last Updated:||June 23, 2021 at 9:00 am|
A thin film topical cream should be applied to the affected areas once a day before bedtime, after washing. The affected areas should be dry before application.
Local reactions include burning, erythema, stinging, pruritus, dry or peeling skin. Increased sensitivity to UVB light or sunlight occurs.
Medapine cream should not come into contact with the eyes, lips mouth and mucous membranes, angles of the nose or broken skin (cuts and abrasions). If product enters the eye, wash with warm water. Because of a potential for increased irritation Medapine cream should not be used by patients with eczema or seborrhoeic dermatitis. If a reaction suggesting severe irritation occurs, discontinue use of the medication. If the irritation is not severe, use the medication less frequently, discontinue use temporarily until symptoms subside, or discontinue use altogether.
Concomitant use of other potentially irritating topical products (medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, products with high concentrations of alcohol, astringents, spices or lime) should be approached with caution.
Exercise particular caution in using preparations containing sulfur, resorcinol or salicylic acid in combination with Medapine.
If any of these preparations have been used, it is advisable not to start therapy with Medapine until the effects of such preparations in skin have subsided. If combined use of both medications is important, it is better to use in two different times.
Food InteractionNo interactions found.
In one clinical study, after ten days of treatment with 2g of 0.3% cream or gel, the terminal half-life was between 7 and 51 hours, with a mean of 17.2 ± 10.2.
Medapine is rapidly cleared from blood plasma, typically undetectable after 72 hours following topical application.
Pregnancy & Breastfeeding use
Pregnancy: Category C. There are no well-controlled studies in pregnant women.
Nursing Mothers: It is not known whether Medapine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Medapine 0.1% cream is administered to a lactating mother.
Medapine should not be administered to individuals who are hypersensitive to Medapine or any of its components.
Safety and effectiveness in children below 12 years of age have not been established.
If the medication is applied excessively, no more rapid or better results will be obtained and marked redness, peeling or discomfort may occur.
Interaction with other Medicine
There are no known interactions with other medications, which might be used topically and concurrently with adapalene topical cream. Other retinoids or drugs with a similar mode of action should not be used concurrently with adapalene. Absorption of adapalene through human skin is low and therefore no interaction with systemic medication.
Store in a cool and dry place (below 25oC). Do not freeze.